# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains Ventyx Biosciences (NASDAQ:VTYX) with a Overweight and lowers the price target f...
Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and lowers the price target from...
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...
Ventyx Biosciences stock down over 24% on Monday after Phase 2 trial results for Crohn's disease drug VTX958 did not meet p...